France‑based Ocean Diagnostics reported that a one‑year pilot study at Bordeaux University Hospital showed its rapid sepsis identification test matched all bloodstream infections detected by conventional blood cultures and identified additional pathogens missed by culture. The test combines high‑volume sample prep, pan‑bacterial PCR, nanopore sequencing and a 1,000‑pathogen database and currently yields results in about five hours. Principal investigator Antoine Dewitte said the prospective observational study enrolled 110 ICU patients and compared the Ocean Dx assay with standard blood culture followed by MALDI‑TOF mass spectrometry. Ocean Diagnostics plans clinical trials to pursue CE marking and later U.S. FDA clearance with the goal of a commercial launch in 2028. If validated in larger trials, the platform could shorten time to targeted therapy in bloodstream infections, reduce empiric broad‑spectrum antibiotic use, and alter sepsis management pathways in critical care.